Skip to main content

Table 2 Clinical information of each ECI group in meta data of breast cancer

From: Transcriptome-wide analysis reveals potential roles of CFD and ANGPTL4 in fibroblasts regulating B cell lineage for extracellular matrix-driven clustering and novel avenues for immunotherapy in breast cancer

 

Level

ECIHigh

ECILow

P

n

 

3368

3368

 

Subtype (%)

Basal

726 (21.6)

337 (10.0)

< 0.001

Her2

537 (15.9)

197 (5.8)

 

LumA

931 (27.6)

2085 (61.9)

 

LumB

1011 (30.0)

468 (13.9)

 

Normal

163 (4.8)

281 (8.3)

 

T_stage (%)

T1

1158 (34.4)

1856 (55.1)

< 0.001

T2

1958 (58.1)

1366 (40.6)

 

T3

252 (7.5)

146 (4.3)

 

N_stage (%)

LN_Negative

1725 (53.1)

1980 (60.2)

< 0.001

LN_Positive

1523 (46.9)

1309 (39.8)

 

Grade (%)

Grade_1

157 (5.9)

518 (19.9)

< 0.001

Grade_2

1000 (37.5)

1381 (53.1)

 

Grade_3

1511 (56.6)

703 (27.0)

 

Age (%)

< = 35

94 (2.8)

87 (2.6)

< 0.001

> = 60

2090 (62.1)

1631 (48.4)

 

35 ~ 60

1184 (35.2)

1650 (49.0)

 

Chemotherapy (%)

No

1701 (61.2)

1857 (66.0)

< 0.001

Yes

1080 (38.8)

957 (34.0)

 

Hormonal_therapy (%)

No

482 (37.7)

277 (36.6)

0.681

Yes

798 (62.3)

479 (63.4)

 

Menopausal (%)

Post_Menopausal

957 (82.4)

491 (71.9)

< 0.001

Pre_Menopausal

204 (17.6)

192 (28.1)

Â